Search
Results: 15
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP)
James L Alexander, Nicholas A Kennedy, Hajir Ibraheim, Sulak Anandabaskaran, Aamir Saifuddin, Rocio Castro Seoane, Zhigang Liu, Rachel Nice, Claire Bewshea, Andrea D'Mello, Laura Constable, Gareth R Jones, Sharmili Balarajah, Francesca Fiorentino, Shaji Sebastian, Peter M Irving, Lucy C Hicks, Horace RT Williams, Alexandra J Kent, Rachel Linger, Miles Parkes, Klaartje Kok, Kamal V Patel, Julian P Teare, Daniel M Altmann, Rosemary J Boyton, James R Goodhand, Ailsa L Hart, Charlie W Lees, Tariq Ahmad, Nick Powell, VIP study investigators
Mar 09, 2022
BACKGROUND: The effects that therapies for inflammatory bowel disease (IBD) have on immune responses to SARS-CoV-2 vaccination are not yet fully known. Therefore, we sought to determine whether COVID-19 vaccine-induced antibody...
SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa.
Adam Abdullahi, David Oladele, Michael Owusu, Steven A Kemp, James Ayorinde, Abideen Salako, Douglas Fink, Fehintola Ige, Isabella ATM Ferreira, Bo Meng, Augustina Angelina Sylverken, Chika Onwuamah, Kwame Ofori Boadu, Kazeem Osuolale, James Opoku Frimpong, Rufai Abubakar, Azuka Okuruawe, Haruna Wisso Abdullahi, Gideon Liboro, Lawrence Duah Agyemang, Nana Kwame Ayisi-Boateng, Oluwatosin Odubela, Gregory Ohihoin, Oliver Ezechi, Japhet Senyo Kamasah, Emmanuel Ameyaw, Joshua Arthur, Derrick Boakye Kyei, Dorcas Ohui Owusu, Olagoke Usman, Sunday Mogaji, Adedamola Dada, George Agyei, Soraya Ebrahimi, Lourdes Ceron Gutierrez, Sani H Aliyu, Rainer Doffinger, Rosemary Audu, Richard Adegbola, Petra Mlcochova, Richard Odame Phillips, Babatunde Lawal Solako, Ravindra K Gupta
Nov 17, 2022
Real-world data on vaccine-elicited neutralising antibody responses for two-dose AZD1222 in African populations are limited. We assessed baseline SARS-CoV-2 seroprevalence and levels of protective neutralizing antibodies prior...
Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
Zoya G Georgieva, Rainer Dӧffinger, Dinakantha Kumararatne, Alasdair J Coles, Claire McCarthy
May 25, 2022
BACKGROUND: Despite impressive efficacy in immunocompetent individuals, the immunogenicity of a single dose of COVID-19 vaccine in B-cell-deplete patients remains unknown. OBJECTIVES: We aimed to quantify real-world vaccine...
Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events
William N Whiteley, Samantha Ip, Jennifer A Cooper, Thomas Bolton, Spencer Keene, Venexia Walker, Rachel Denholm, Ashley Akbari, Efosa Omigie, Sam Hollings, Emanuele Di Angelantonio, Spiros Denaxas, Angela Wood, Jonathan AC Sterne, Cathie Sudlow, CVD-COVID-UK Consortium
Mar 28, 2022
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Simeng Lin, Nicholas A Kennedy, Aamir Saifuddin, Diana Muñoz Sandoval, Catherine J Reynolds, Rocio Castro Seoane, Sherine H Kottoor, Franziska P Pieper, Kai-Min Lin, David K Butler, Neil Chanchlani, Rachel Nice, Desmond Chee, Claire Bewshea, Malik Janjua, Timothy J McDonald, Shaji Sebastian, James L Alexander, Laura Constable, James C Lee, Charles D Murray, Ailsa L Hart, Peter M Irving, Gareth-Rhys Jones, Klaartje B Kok, Christopher A Lamb, Charlie W Lees, Daniel M Altmann, Rosemary J Boyton, James R Goodhand, Nick Powell, Tariq Ahmad, CLARITY IBD study
Apr 19, 2022
Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection and impair protective immunity following pneumococcal and influenza vaccination. Here we report SARS-CoV-2 vaccine-induced immune...
A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice.
Alyssa Silva-Cayetano, William S Foster, Silvia Innocentin, Sandra Belij-Rammerstorfer, Alexandra J Spencer, Oliver T Burton, Sigrid Fra-Bidó, Jia Le Lee, Nazia Thakur, Carina Conceicao, Daniel Wright, Jordan Barrett, Nicola Evans-Bailey, Carly Noble, Dalan Bailey, Adrian Liston, Sarah C Gilbert, Teresa Lambe, Michelle A Linterman
Feb 19, 2021
BACKGROUND: The spread of SARS-CoV-2 has caused a worldwide pandemic that has affected almost every aspect of human life. The development of an effective COVID-19 vaccine could limit the morbidity and mortality caused by...
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK
Xinxue Liu, Alasdair PS Munro, Shuo Feng, Leila Janani, Parvinder K Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Wanwisa Dejnirattisai, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L Goodman, Christopher A Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A van der Klaauw, Jonathan Kwok, Vincenzo Libri, Martin J Llewelyn, Alastair C McGregor, Angela M Minassian, Patrick Moore, Mehmood Mughal, Yama F Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Teona Serafimova, Dinesh Saralaya, Gavin R Screaton, Sunil Sharma, Ray Sheridan, Ann Sturdy, Piyada Supasa, Emma C Thomson, Shirley Todd, Chris Twelves, Robert C Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S Nguyen-Van-Tam, Victoria Cornelius, Matthew D Snape, Saul N Faust, COV-BOOST study group
May 13, 2022
OBJECTIVES: To evaluate the persistence of immunogenicity three months after third dose boosters. METHODS: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster...
COVID-19 vaccine Fractional dose Heterologous boost Homologous boost Immunogenicity Persistence Third dose Ad26COVS1 Adult Aged Aged 80 and over Antibodies Viral BNT162 Vaccine covid-19 COVID-19 Vaccines ChAdOx1 nCoV-19 Humans Immunogenicity Vaccine Immunoglobulin G Middle Aged SARS-CoV-2 United Kingdom Viral Vaccines mRNA Vaccines
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2
Merryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, Lily Y Weckx, Pedro M Folegatti, Parvinder K Aley, Brian Angus, Vicky L Baillie, Shaun L Barnabas, Qasim E Bhorat, Sagida Bibi, Carmen Briner, Paola Cicconi, Andrea M Collins, Rachel Colin-Jones, Clare L Cutland, Thomas C Darton, Keertan Dheda, Christopher JA Duncan, Katherine RW Emary, Katie J Ewer, Lee Fairlie, Saul N Faust, Shuo Feng, Daniela M Ferreira, Adam Finn, Anna L Goodman, Catherine M Green, Christopher A Green, Paul T Heath, Catherine Hill, Helen Hill, Ian Hirsch, Susanne HC Hodgson, Alane Izu, Susan Jackson, Daniel Jenkin, Carina CD Joe, Simon Kerridge, Anthonet Koen, Gaurav Kwatra, Rajeka Lazarus, Alison M Lawrie, Alice Lelliott, Vincenzo Libri, Patrick J Lillie, Raburn Mallory, Ana VA Mendes, Eveline P Milan, Angela M Minassian, Alastair McGregor, Hazel Morrison, Yama F Mujadidi, Anusha Nana, Peter J O'Reilly, Sherman D Padayachee, Ana Pittella, Emma Plested, Katrina M Pollock, Maheshi N Ramasamy, Sarah Rhead, Alexandre V Schwarzbold, Nisha Singh, Andrew Smith, Rinn Song, Matthew D Snape, Eduardo Sprinz, Rebecca K Sutherland, Richard Tarrant, Emma C Thomson, M Estée Török, Mark Toshner, David PJ Turner, Johan Vekemans, Tonya L Villafana, Marion EE Watson, Christopher J Williams, Alexander D Douglas, Adrian VS Hill, Teresa Lambe, Sarah C Gilbert, Andrew J Pollard, Oxford COVID Vaccine Trial Group
Dec 23, 2020
BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety...
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
Nicholas A Kennedy, Simeng Lin, James R Goodhand, Neil Chanchlani, Benjamin Hamilton, Claire Bewshea, Rachel Nice, Desmond Chee, JR Fraser Cummings, Aileen Fraser, Peter M Irving, Nikolaos Kamperidis, Klaartje B Kok, Christopher Andrew Lamb, Jonathan Macdonald, Shameer Mehta, Richard Cg Pollok, Tim Raine, Philip J Smith, Ajay Mark Verma, Simon Jochum, Timothy J McDonald, Shaji Sebastian, Charlie W Lees, Nick Powell, Tariq Ahmad, Contributors to the CLARITY IBD study
Apr 28, 2021
OBJECTIVE: Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more of the population. We investigated whether patients with inflammatory bowel disease treated with...
BNT162b2 CLARITY covid-19 ChAdOx1 nCoV-19 TNF Autoimmune Disease inflammatory bowel disease inflammatory diseases Infliximab vaccine vedolizumab Adult Antibodies Monoclonal Humanized Antibodies Viral Antibody Formation BNT162 Vaccine covid-19 COVID-19 Vaccines ChAdOx1 nCoV-19 Female Gastrointestinal Agents Humans Inflammatory Bowel Diseases Infliximab Male Middle Aged SARS-CoV-2 Serologic Tests
Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing
Julia Hippisley-Cox, Martina Patone, Xue W Mei, Defne Saatci, Sharon Dixon, Kamlesh Khunti, Francesco Zaccardi, Peter Watkinson, Manu Shankar-Hari, James Doidge, David A Harrison, Simon J Griffin, Aziz Sheikh, Carol AC Coupland
Sep 09, 2021
OBJECTIVE: To assess the association between covid-19 vaccines and risk of thrombocytopenia and thromboembolic events in England among adults. DESIGN: Self-controlled case series study using national data on covid-19 vaccination...
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7)
Katherine RW Emary, Tanya Golubchik, Parvinder K Aley, Cristina V Ariani, Brian Angus, Sagida Bibi, Beth Blane, David Bonsall, Paola Cicconi, Sue Charlton, Elizabeth A Clutterbuck, Andrea M Collins, Tony Cox, Thomas C Darton, Christina Dold, Alexander D Douglas, Christopher JA Duncan, Katie J Ewer, Amy L Flaxman, Saul N Faust, Daniela M Ferreira, Shuo Feng, Adam Finn, Pedro M Folegatti, Michelle Fuskova, Eva Galiza, Anna L Goodman, Catherine M Green, Christopher A Green, Melanie Greenland, Bassam Hallis, Paul T Heath, Jodie Hay, Helen C Hill, Daniel Jenkin, Simon Kerridge, Rajeka Lazarus, Vincenzo Libri, Patrick J Lillie, Catherine Ludden, Natalie G Marchevsky, Angela M Minassian, Alastair C McGregor, Yama F Mujadidi, Daniel J Phillips, Emma Plested, Katrina M Pollock, Hannah Robinson, Andrew Smith, Rinn Song, Matthew D Snape, Rebecca K Sutherland, Emma C Thomson, Mark Toshner, David PJ Turner, Johan Vekemans, Tonya L Villafana, Christopher J Williams, Adrian VS Hill, Teresa Lambe, Sarah C Gilbert, Merryn Voysey, Maheshi N Ramasamy, Andrew J Pollard, COVID-19 Genomics UK Consortium, AMPHEUS Project, Oxford COVID-19 Vaccine Trial Group
May 06, 2021
BACKGROUND: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19...
Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.
Shona C Moore, Barbara Kronsteiner, Stephanie Longet, Sandra Adele, Alexandra S Deeks, Chang Liu, Wanwisa Dejnirattisai, Laura Silva Reyes, Naomi Meardon, Sian Faustini, Saly Al-Taei, Tom Tipton, Luisa M Hering, Adrienn Angyal, Rebecca Brown, Alexander R Nicols, Susan L Dobson, Piyada Supasa, Aekkachai Tuekprakhon, Andrew Cross, Jessica K Tyerman, Hailey Hornsby, Irina Grouneva, Megan Plowright, Peijun Zhang, Thomas AH Newman, Jeremy M Nell, Priyanka Abraham, Mohammad Ali, Tom Malone, Isabel Neale, Eloise Phillips, Joseph D Wilson, Sam M Murray, Martha Zewdie, Adrian Shields, Emily C Horner, Lucy H Booth, Lizzie Stafford, Sagida Bibi, Daniel G Wootton, Alexander J Mentzer, Christopher P Conlon, Katie Jeffery, Philippa C Matthews, Andrew J Pollard, Anthony Brown, Sarah L Rowland-Jones, Juthathip Mongkolsapaya, Rebecca P Payne, Christina Dold, Teresa Lambe, James ED Thaventhiran, Gavin Screaton, Eleanor Barnes, Susan Hopkins, Victoria Hall, Christopher JA Duncan, Alex Richter, Miles Carroll, Thushan I de Silva, Paul Klenerman, Susanna Dunachie, Lance Turtle, PITCH Consortium
Apr 02, 2023
BACKGROUND: Both infection and vaccination, alone or in combination, generate antibody and T cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the maintenance of such responses-and...
Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis.
Brian Craven, William Lester, Sara Boyce, Will Thomas, Angela Kanny, Claire Davies, Sue Pavord, Joannes Hermans, Michael Makris, Emily Bart-Smith, Sarah Arnott, Beverley J Hunt, Pavel Chudakou, Anthony Calvert, Deepak Singh, Marie Scully
Apr 09, 2022
The COVID-19 pandemic has resulted in the rapid development of a range of vaccines against SARS-CoV-2. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare but life-threatening complication of primarily...
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST)
Alasdair PS Munro, Shuo Feng, Leila Janani, Victoria Cornelius, Parvinder K Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L Goodman, Christopher A Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A van der Klaauw, Nasir Kanji, Vincenzo Libri, Martin J Llewelyn, Alastair C McGregor, Mina Maallah, Angela M Minassian, Patrick Moore, Mehmood Mughal, Yama F Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Tanveer Bawa, Dinesh Saralaya, Sunil Sharma, Ray Sheridan, Emma C Thomson, Shirley Todd, Chris Twelves, Robert C Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S Nguyen-Van-Tam, Matthew D Snape, Xinxue Liu, Saul N Faust, COV-BOOST study group
Jun 13, 2022
BACKGROUND: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety...
Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation
Adrian M Shields, Sian E Faustini, Harriet J Hill, Saly Al-Taei, Chloe Tanner, Fiona Ashford, Sarita Workman, Fernando Moreira, Nisha Verma, Hollie Wagg, Gail Heritage, Naomi Campton, Zania Stamataki, Mark T Drayson, Paul Klenerman, James ED Thaventhiran, Shuayb Elkhalifa, Sarah Goddard, Sarah Johnston, Aarnoud Huissoon, Claire Bethune, Suzanne Elcombe, David M Lowe, Smita Y Patel, Sinisa Savic, Alex G Richter, Siobhan O Burns, COV-AD consortium
Jun 16, 2022
BACKGROUND: Patients with primary and secondary antibody deficiency are vulnerable to COVID-19 and demonstrate diminished responses following two-dose SARS-CoV-2 vaccine schedules. Third primary vaccinations have been deployed...